$66.72
-0.31[-0.46%]
At close: Apr 24
$66.72
0[0.00%]
PreMarket: 8:02AM EDT
Gilead Sciences
(NASDAQ:GILD)Latest News for Gilead Sciences Stock (NASDAQ:GILD)
Gilead Sciences Stock (NASDAQ: GILD)
Categories: All
Sunday, April 21, 2024
Friday, April 19, 2024
- Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024Benzinga Newsdesk - 4 days ago
- The Analyst Verdict: Gilead Sciences In The Eyes Of 12 ExpertsBenzinga Insights - 4 days ago
- Oppenheimer Maintains Outperform on Gilead Sciences, Maintains $105 Price TargetBenzinga Newsdesk - 4 days ago
- FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer TherapiesVandana Singh - 4 days ago
Thursday, April 18, 2024
Wednesday, April 17, 2024
Thursday, April 11, 2024
Tuesday, April 09, 2024
Monday, April 08, 2024
Friday, April 05, 2024
Wednesday, April 03, 2024
- 10 Health Care Stocks Whale Activity In Today's SessionBenzinga Insights - Apr 3, 2024, 1:35PM
- CORRECTION: Wells Fargo On Mar. 4 Lowered Gilead PT From $84 To $78Benzinga Newsdesk - Apr 3, 2024, 11:55AM
- If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 TodayBenzinga Insights - Apr 3, 2024, 10:30AM
Monday, April 01, 2024
Thursday, March 28, 2024
- Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's WhyVandana Singh - Mar 28, 2024, 12:39PM
- FDA Expands Indication For Gilead's Vemlidy To Treat Chronic HBV Infection In Pediatric PatientsBenzinga Newsdesk - Mar 28, 2024, 8:33AM
- Gilead, Xilio Enter Exclusive License Deal For Phase 1 Tumor-Activated Il-12 Program, XTX301; Deal Includes $43.5M Upfront, Up To $604M In Additional Contingent PaymentsBenzinga Newsdesk - Mar 28, 2024, 7:04AM
Wednesday, March 27, 2024
Friday, March 22, 2024
Tuesday, March 19, 2024
Friday, March 15, 2024
Monday, March 11, 2024
Friday, March 08, 2024
Thursday, March 07, 2024
Wednesday, March 06, 2024
- Gilead Sciences, Inc. Announces New Data From Three Studies Evaluating The Efficacy And Safety Profile Of Biktarvy, Demonstrating High Rates Of Viral Suppression In People With HIV And ComorbiditiesHappy Mohamed - Mar 6, 2024, 4:47PM
- Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo TherapyVandana Singh - Mar 6, 2024, 4:30PM
- Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, ToddlersVandana Singh - Mar 6, 2024, 4:21PM
- Gilead and Merck Announce Phase 2 Data Showing An Investigational Oral Once-Weekly Combination Regimen Of Islatravir And Lenacapavir Maintained Viral Suppression At Week 24Benzinga Newsdesk - Mar 6, 2024, 10:26AM
- Gilead and Merus Announce Collaboration To Discover Novel Antibody-Based Trispecific T-Cell Engagers; Merus To Receive Upfront Cash Payment Of $56M For Initial Targets And Equity Investment By Gilead Of $25M in Merus Common Shares, Merus Is Also Eligible to Receive Up to $1.5BBenzinga Newsdesk - Mar 6, 2024, 8:05AM
Tuesday, March 05, 2024
Monday, March 04, 2024
Monday, February 26, 2024
- Gilead Sciences Says FDA Approves Expanded Indication For Biktarvy To Treat People With HIV With Suppressed Viral Loads, Pre-existing ResistanceBenzinga Newsdesk - Feb 26, 2024, 4:15PM
- Gilead To Present Late-Breaking Data And Real-World Evidence Highlighting Innovative Antiviral Portfolio And Research Pipeline At CROI 2024Benzinga Newsdesk - Feb 26, 2024, 8:38AM
Friday, February 23, 2024
Thursday, February 22, 2024
Tuesday, February 20, 2024
Friday, February 16, 2024
Wednesday, February 14, 2024
Tuesday, February 13, 2024
Monday, February 12, 2024
- Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3BAvi Kapoor - Feb 12, 2024, 12:30PM
- Health Care Company Gilead Sciences Announces Acquisition of CymaBay TherapeuticsBenzinga Insights - Feb 12, 2024, 10:10AM
- Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3BVandana Singh - Feb 12, 2024, 9:22AM
- Oppenheimer Maintains Outperform on Gilead Sciences, Lowers Price Target to $105Benzinga Newsdesk - Feb 12, 2024, 8:40AM
- Gilead Sciences Expands Liver Portfolio With Acquisition Of CymaBay Therapeutics For $32.50/Share Or A Total Equity Value Of $4.3BBenzinga Newsdesk - Feb 12, 2024, 8:31AM